newsNICE recommends routine access to beta interferon drug for MS21 December 2017 | By Steve Bremer (European Pharmaceutical Review)Multiple sclerosis patients to have routine access to beta interferon drug, says NICE in new draft guidance.
newsOzanimod successful in clinical trials for multiple sclerosis10 November 2017 | By Dr Zara Kassam (European Pharmaceutical Review)The findings from the two pivotal phase 3 trials pave the way for ozanimod to enter the New Drug Approval process with the FDA...